NT5E is associated with unfavorable prognosis and regulates cell proliferation and motility in gastric cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
NT5E is associated with unfavorable prognosis and regulates cell proliferation and motility in gastric cancer
Authors
Keywords
-
Journal
BIOSCIENCE REPORTS
Volume 39, Issue 5, Pages BSR20190101
Publisher
Portland Press Ltd.
Online
2019-04-16
DOI
10.1042/bsr20190101
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers
- (2018) Tao Jiang et al. BMC CANCER
- Tumor-Suppressive Function of miR-30d-5p in Prostate Cancer Cell Proliferation and Migration by Targeting NT5E
- (2018) Yongbo Song et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
- (2018) Jiayin Yang et al. CURRENT MEDICINAL CHEMISTRY
- Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E
- (2018) Theresa Kordaß et al. Frontiers in Immunology
- Detailed analysis of adenosine A2a receptor (ADORA2A) and CD73 (5′-nucleotidase, ecto, NT5E) methylation and gene expression in head and neck squamous cell carcinoma patients
- (2018) Timo J. Vogt et al. OncoImmunology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Activity of ecto-5′-nucleotidase (NT5E/CD73) is increased in papillary thyroid carcinoma and its expression is associated with metastatic lymph nodes
- (2018) Ana Paula Santin Bertoni et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Be Aware of Aggregators in the Search for Potential Human ecto-5′-Nucleotidase Inhibitors
- (2018) Lucas Viviani et al. MOLECULES
- NT5E inhibition suppresses the growth of sunitinib-resistant cells and EMT course and AKT/GSK-3β signaling pathway in renal cell cancer
- (2018) Dan Peng et al. IUBMB LIFE
- The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
- (2017) Bertrand Allard et al. IMMUNOLOGICAL REVIEWS
- Extracellular 5′-nucleotidase (CD73) promotes human breast cancer cells growth through AKT/GSK-3β/β-catenin/cyclinD1 signaling pathway
- (2017) Jiangang Yu et al. INTERNATIONAL JOURNAL OF CANCER
- Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
- (2017) Silvana Morello et al. Journal of Translational Medicine
- CD73/NT5E is a target of miR-30a-5p and plays an important role in the pathogenesis of non-small cell lung cancer
- (2017) Jianjie Zhu et al. Molecular Cancer
- Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer
- (2017) Yusuke Inoue et al. Oncotarget
- CD73–adenosine: a next-generation target in immuno-oncology
- (2016) David Allard et al. Immunotherapy
- Apatinib in treatment of refractory gastric cancer
- (2016) Vicki Brower LANCET ONCOLOGY
- Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer
- (2016) Y Sunakawa et al. PHARMACOGENOMICS JOURNAL
- CD73 is associated with poor prognosis in HNSCC
- (2016) Zhen-Hu Ren et al. Oncotarget
- MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinoma
- (2016) Nathalie Bonnin et al. Oncotarget
- Bioorthogonal labeling cell-surface proteins expressed in pancreatic cancer cells to identify potential diagnostic/therapeutic biomarkers
- (2015) Randy S Haun et al. CANCER BIOLOGY & THERAPY
- CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer
- (2015) Martin Turcotte et al. CANCER RESEARCH
- Loss of CD73-mediated actin polymerization promotes endometrial tumor progression
- (2015) Jessica L. Bowser et al. JOURNAL OF CLINICAL INVESTIGATION
- Identification of Serum Biomarkers for Gastric Cancer Diagnosis Using a Human Proteome Microarray
- (2015) Lina Yang et al. MOLECULAR & CELLULAR PROTEOMICS
- Effects of CD73 on human colorectal cancer cell growth in vivo and in vitro
- (2015) RUIMIN WU et al. ONCOLOGY REPORTS
- Gastric Cancer: Descriptive Epidemiology, Risk Factors, Screening, and Prevention
- (2014) P. Karimi et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)
- (2014) S. M. Cushman et al. CLINICAL CANCER RESEARCH
- High Expression of Ecto-Nucleotidases CD39 and CD73 in Human Endometrial Tumors
- (2014) Elisabet Aliagas et al. MEDIATORS OF INFLAMMATION
- NT5E and FcGBP as key regulators of TGF-1-induced epithelial–mesenchymal transition (EMT) are associated with tumor progression and survival of patients with gallbladder cancer
- (2013) Li Xiong et al. CELL AND TISSUE RESEARCH
- Overexpression of CD73 in Prostate Cancer is Associated with Lymph Node Metastasis
- (2013) Qing Yang et al. PATHOLOGY & ONCOLOGY RESEARCH
- CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
- (2013) S. Loi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma
- (2013) Xiao-Xia Lu WORLD JOURNAL OF GASTROENTEROLOGY
- High expression of CD73 as a poor prognostic biomarker in human colorectal cancer
- (2012) Xian-Rui Wu et al. JOURNAL OF SURGICAL ONCOLOGY
- Gastric cancer epidemiology and risk factors
- (2012) Douglas E. Guggenheim et al. JOURNAL OF SURGICAL ONCOLOGY
- CD73 (5′-nucleotidase) expression has no prognostic value in children with acute lymphoblastic leukemia
- (2011) E Wieten et al. LEUKEMIA
- CD73 Expression as a Potential Marker of Good Prognosis in Breast Carcinoma
- (2011) Anna Supernat et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started